XCancer

3D1015 Injection for Patients With mCRPC

Description:

This open-label clinical study investigates 3D1015 Injection (Lu 177-PSMA-3D1015) in adult males with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). Participants will receive intravenous infusions of 3D1015, with treatment regimens dynamically individualized to optimize patient safety and outcomes. The primary objectives are to assess the safety, tolerability, and dosimetry of the injection. Secondary objectives include evaluating preliminary anti-tumor efficacy and exploring the optimal dosing regimen.

Sponsor:

Affiliated Hospital of Jiangnan University

Phase:

Phase 1

Contacts:

chunjing Yu (CONTACT)

ycjwxd1978@jiangnan.edu.cn

15312238622

Government Study Link:

NCT07537010 - Click here to see study on

ClinicalTrials.gov

PSMA-3D1015

Isotope(s):
Target(s):
  • PSMA
Ligand Class: Small Molecules
Inclusion
  • Presence of at least one metastatic lesion at baseline.
  • Histologically or cytologically confirmed prostate adenocarcinoma.
  • Confirmed progressive metastatic castration-resistant prostate cancer (mCRPC) that is refractory to or has progressed following prior treatments.
Exclusion
  • A superscan as seen in the baseline bone scan.
  • Receipt of other systemic anti-cancer therapies within 4 weeks prior to study entry.